A Single-center Pilot Study Evaluating the Immediate Effects of Low-dose Acetazolamide on Respiratory Control in Subjects With Treatment Emergent Sleep Disordered Breathing

• Status: Withdrawn
• Trial end date: 2017-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a single center pilot study evaluating the immediate effects of low-dose acetazolamide on respiratory control in subjects with treatment emergent sleep disordered breathing. The purpose of this study is to assess the immediate effect one-time low-dose acetazolamide on sleep breathing in (Treatment Emergent Sleep Disordered Breathing) TE-CSA subjects compared to subjects' baseline evaluation without acetazolamide. Investigators will also try to determine the immediate effect of one-time low-dose acetazolamide on subjects' resting ventilation and ventilatory response slope compared to subjects' baseline evaluation without acetazolamide.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: New York University School of Medicine; NYU Langone Health
• Treatments: Acetazolamide

Criteria

Inclusion Criteria:

• Age ≥18 to 80 years

• TE-CSA

• Subjects are capable of giving informed consent

Exclusion Criteria:

• Hypersensitivity to acetazolamide or other sulfonamides

• Intake of carbonic anhydrase inhibitors within the last 72 hours

• Intake of medication that influences breathing, sleep, arousal or muscle physiology

• Cheyne-Stokes respiration

• Heart failure

• Renal failure

• Liver failure

• Chronic hypercapnea

• Hyponatremia

• Hypokalemia

• Pregnancy

• Breastfeeding mothers

• Active drug/alcohol dependence or abuse history